// App-Quantinova.ai

THU0195 : INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM

Researchers

Presenter

  • E. Choy

Principal Investigators

  • I. Mcinnes

  • J. Cush

  • J. Aelion

  • W. Rigby

  • Y. Song

  • S. Meerwein

  • J. Liu

  • N. Khan

  • J. Suboticki

  • A. Cohen

Medical Centers

  • CREATE Centre, Cardiff University, Cardiff, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • University of Texas Southwestern Medical School, Dallas, United States of America

  • Arthritis Clinic PLLC, Jackson, United States of America

  • Dartmouth-Hitchcock Medical Center, Lebanon, United States of America

  • Guy’s and St Thomas’ NHS FT Hospitals, King’s College London, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • Methotrexate

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved